VPF/VEGF in normal and neoplastic skin angiogenesis

Information

  • Research Project
  • 7393824
  • ApplicationId
    7393824
  • Core Project Number
    R01CA069184
  • Full Project Number
    5R01CA069184-13
  • Serial Number
    69184
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/14/1996 - 28 years ago
  • Project End Date
    2/28/2010 - 14 years ago
  • Program Officer Name
    BAKER, CARL
  • Budget Start Date
    3/1/2008 - 16 years ago
  • Budget End Date
    2/28/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    13
  • Suffix
  • Award Notice Date
    1/31/2008 - 16 years ago
Organizations

VPF/VEGF in normal and neoplastic skin angiogenesis

[unreadable] DESCRIPTION (provided by applicant): [unreadable] The overall objective of our research is to characterize the molecular mechanisms that regulate the generation and function of blood vessels and lymphatic vessels in the skin. Our previous studies have identified vascular endothelial growth factor (VEGF) as a cytokine of central importance for normal, inflammatory and neoplastic skin angiogenesis that may also induce lymphatic vessel growth. VEGF overexpressing transgenic mice develop chronic inflammatory skin lesions that histologically resemble human psoriasis. We have also identified a critical role of VEGF-C in tumor lymphangiogenesis and lymph node metastasis. Moreover, we established a new in vitro model for the isolation of human dermal lymphatic and blood vascular endothelial cells that maintain lineage-specific differentiation even after multiple passages in vitro and that show specific responses to growth factor stimulation. We now propose experiments to test our specific hypotheses: (1) that VEGF plays a critical role in the induction and maintenance of skin inflammation, (2) that VEGF-C promotes lymphangiogenesis predominantly via activation of VEGFR-3 whereas VEGF-induced lymphangiogenesis is mediated through activation of VEGFR-2 and through indirect effects via induction of vascular hyperpermeability, and (3) that VEGF predominantly promotes skin cancer angiogenesis and organ metastasis whereas VEGF-C promotes tumor lymphangiogenesis and lymph node metastasis. Therefore, we propose to: 1. Define the importance of VEGF for cutaneous inflammation, characterizing the spontaneous and provoked, psoriasis-like skin inflammation in VEGF transgenic mice, determining the anti-inflammatory activity of VEGF receptor blockade, and identifying VEGF target genes involved in skin inflammation; 2. Define the mechanisms of VEGF versus VEGF-C-induced skin lymphangiogenesis, comparing induced lymphatic vessel formation and function in VEGF and VEGF-C transgenic mice and determining the distinct impact of VEGF and VEGF-C on gene expression and function of cultured dermal lymphatic endothelial cells; 3. Define the role of VEGF and VEGF-C in cutaneous tumor lymphangiogenesis and lymphatic versus organ metastasis in genetically fluorescent transgenic mice. [unreadable] [unreadable] At the conclusion of our studies, we will have assessed the importance of VEGF and VEGF-C for skin inflammation, angiogenesis and lymphangiogenesis, and we will have identified mechanisms that might serve as potential targets for the development of novel therapies for inflammatory skin diseases and skin cancer. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    145925
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:145925\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SWISS FEDERAL INST OF TECH (ETH ZURICH)
  • Organization Department
  • Organization DUNS
    481907673
  • Organization City
    ZURICH
  • Organization State
  • Organization Country
    SWITZERLAND
  • Organization Zip Code
    8092
  • Organization District
    SWITZERLAND